Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE

Infex Therapeutics, an anti-infectives specialist, has announced that in collaboration with Justus-Liebig-University Giessen, it has been awarded a £1 million grant from PACE, to develop a BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens.

BamA inhibitors are an entirely new class of antimicrobial drug designed to target infections caused by drug-resistant Gram-negative bacteria. BamA is a key novel protein specific to Gram-negative bacteria that was previously considered undruggable. By blocking BamA, these inhibitors weaken the bacteria’s…